Ογ½ΆΚΣΖ΅

Skip to main content
Robert L. Dood
( out of 247 reviews )

Robert L. Dood, MD, MSCE

Languages spoken: English, Spanish

Clinical Locations

Sugar House Health Center

Salt Lake City
801-581-2000
  • Robert Dood, MD MSCE is a gynecologic oncologist and assistant professor at the Ογ½ΆΚΣΖ΅ of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

    His research interests include implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

    After completing his Bachelor of Science (BS) degree in Biochemistry from the Ογ½ΆΚΣΖ΅ of Michigan with High Distinction, he attended the Perelman School of Medicine at the Ογ½ΆΚΣΖ΅ of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the Ογ½ΆΚΣΖ΅ of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the Ογ½ΆΚΣΖ΅ of Texas MD Anderson Cancer Center.

    Patient Rating

    4.9 /5
    ( out of 247 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 28, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr Dood has helped me through my cancer journey with a rare cancer. He is so attentive, and his manner is extremely comforting.

    March 15, 2025
    SUGAR HOUSE HEALTH CENTER

    Excellent at explaining options for treatment. Easy manner, and rapport with his team which created a comfortable atmosphere during the appointment. Explained all options for future treatment clearly.

    March 14, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood is extremely professional and thorough in his care and treatment. He takes the time to explain issues that are pertinent and goes over the course of treatment.

    March 14, 2025
    SUGAR HOUSE HEALTH CENTER

    I love Dr. DOOD. HE IS VERY NICE, PATIENT, KIND AND INTELLIGENT. HE AND HIS STAFF RUN AN EXCELLENT OFFICE.

    February 28, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood had a good personality he was very proud as he knew what he was doing. I'm grateful to be able to meet him. Thank you for the care I received ? mk

    February 28, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr Dood is kind, caring and always listens to me. I always receive excellent care from him.

    February 20, 2025
    HUNTSMAN CANCER CENTER

    Dr. Dood is the very best, I would recommend him to everyone who needed his expertise.

    February 13, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood is the consummate caring provider. He is professional, considerate and genuinely interested in me and my health. He puts me at ease and explains things thoroughly and sensitively.

    February 06, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood is absolutely the best. I very much appreciate his cautious approach to treatment, striving to do the least invasive procedure possible. He's a brilliant diagnostician. He is extremely caring and compassionate. He works diligently to understand the patient's condition, and collaborates with peers to gain insight. He went above and beyond expectations to keep me informed about my condition, and explain treatment recommendations. He's definitely a 5 star doctor!

  • Robert Dood, MD MSCE is a gynecologic oncologist and assistant professor at the Ογ½ΆΚΣΖ΅ of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

    His research interests include implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

    After completing his Bachelor of Science (BS) degree in Biochemistry from the Ογ½ΆΚΣΖ΅ of Michigan with High Distinction, he attended the Perelman School of Medicine at the Ογ½ΆΚΣΖ΅ of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the Ογ½ΆΚΣΖ΅ of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the Ογ½ΆΚΣΖ΅ of Texas MD Anderson Cancer Center.

    Board Certification and Academic Information

    Academic Departments Obstetrics & Gynecology -Assistant Professor
    Academic Divisions Gynecological Oncology

    Selected Publications

    Journal Article

    1. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA (2018). Defining Survivorship Trajectories Across Patients with Solid Tumors: An Evidence-Based Approach. JAMA Oncol, 4(11), 1519-1526. ()
    2. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK (2018). When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer, 28(8), 1485-1490. ()
    3. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2018). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 3(11). ()
    4. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK (2017). Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther, 17(2), 464-473. ()
    5. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK (2017). Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 8(57), 96496-96505. ()
    6. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017). Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun, 8(1), 310. ()
    7. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2017). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2(16). ()
    8. Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS (2017). Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res, 77(11), 2903-2913. ()
    9. Dood RL, Gracia CR, Sammel MD, Haynes K, Senapati S, Strom BL (2014). Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol, 21(5), 744-52. ()

    Letter

    1. Dood RL (2014). Reply: To PMID 24590007. [Letter to the editor]. J Minim Invasive Gynecol, 22(3), 510. ()